Galen Ltd, the Northern Ireland based pharmaceutical company, has announced the appointment of Dr Dennise Broderick as its new Managing Director and President. She will report to Alan Armstrong, CEO and Chairman, Almac Group - the parent company of Galen Ltd.
Together with Almac Group’s Board of Directors, Dr Broderick is responsible for all aspects of the specialist pharmaceutical company’s operations, marketing and governance across its sites throughout Europe and the US.
Dr Broderick is a highly successful, respected and inspiring Executive Business Leader, with an extensive career within the pharmaceutical industry. Most recently she held the position of Country Manager, leading the Irish affiliate of IPSEN Pharmaceuticals and was responsible for all aspects of the business. Prior to this Dr Broderick also held CEO/MD and senior leadership roles with Pfizer, Hospira, Zeneus, Viatris and other pharmaceutical companies in Ireland and Europe.
Dr Broderick highly respected academically and remains on the invite list as a guest lecturer within the National Universities of Ireland, having previously lectured part-time within their network.
Mr Armstrong, commented on Dr Broderick's appointment: “We are delighted to welcome Dennise to our team. Her inside knowledge of the industry will be instrumental in developing the Galen brand and growing the company globally. Her inspiring approach will be sure to help us meet our ambitious targets and look forward to an exciting future.”
